Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

10368	Companies
215940	Keywords
145686	Articles
114363	Press releases

Home
Companies
Biophytis

BRIEF

published on 04/22/2025 at 07:05, 1 year ago

Biophytis et son avancée dans le traitement de l'obésité

Biophytis Marché Mondial Obésité GLP-1 Masse Musculaire
BRIEF

published on 04/22/2025 at 07:05, 1 year ago

Biophytis Aims for Enhanced Mobility in Obesity Treatment

Biophytis Obesity Treatment Muscle Preservation GLP-1 Therapies Biotechnology Market
REGULATED PRESS RELEASE

published on 04/22/2025 at 07:00, 1 year ago

Biophytis cible la restauration de la mobilité chez les patients obèses
Biophytis développe des traitements pour restaurer la mobilité des patients obèses. Leur candidat-médicament BIO101, combiné avec GLP-1, améliore la force musculaire. Vers une nouvelle génération de thérapies axées sur la qualité de la perte de poids

Biophytis Mobilite BIO101 Obésité GLP-1
REGULATED PRESS RELEASE

published on 04/22/2025 at 07:00, 1 year ago

Biophytis targets mobility restoration in patients with obesity
Biophytis strengthens position in developing treatments for age-related muscle function loss in obesity care by focusing on quality weight loss and mobility restoration with BIO101 and GLP-1 therapies

Biophytis Muscle Function Obesity Care Quality Weight Loss Mobility Restoration
PRESS RELEASE

published on 04/22/2025 at 06:59, 1 year ago

Biophytis targets mobility restoration in patients with obesity
Biophytis focuses on preserving muscle function in obesity patients treated with GLP-1 therapies by developing BIO101. The aim is to improve quality of weight loss and mobility

Biophytis BIO101 Obesity Muscle Function GLP-1 Therapies
BRIEF

published on 04/09/2025 at 07:05, 1 year ago

Biophytis lance la phase 2 de l'essai clinique OBA pour l'obésité

Investissement Biophytis Essai Clinique BIO101 Obésité
BRIEF

published on 04/09/2025 at 07:05, 1 year ago

Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment

Biophytis Obesity Treatment Clinical Trial BIO101 Partnership Goal
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 1 year ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the Phase 2 OBA Clinical Trial launch in obesity, continuing development of BIO101 to reduce muscle strength loss. Seeking pharmaceutical partner for co-development

Biophytis BIO101 Obesity Pharmaceutical Partner Phase 2 OBA Clinical Trial
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 1 year ago

Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité
Biophytis confirme le lancement de l'essai clinique de Phase 2 OBA dans l'obésité en 2025, avec BIO101. Recherche d'un partenaire pharmaceutique pour le développement et le lancement du produit aux États-Unis

Biophytis Essai Clinique BIO101 Obésité Partenaire Pharmaceutique
PRESS RELEASE

published on 04/09/2025 at 06:59, 1 year ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients

Biophytis BIO101 Obesity Muscle Strength Phase 2 OBA Clinical Trial

Accesswire

Published on 05/07/2026 at 22:05, 49 minutes ago

MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications
Published on 05/07/2026 at 22:05, 49 minutes ago

Innodata Reports Record First Quarter 2026 Results
Published on 05/07/2026 at 18:30, 4 hours 24 minutes ago

Silver Storm Announces Mobilization of Underground Mine Development Contractors at La Parrilla
Published on 05/07/2026 at 16:35, 6 hours 19 minutes ago

Caledonia Mining Corporation Plc New Corporate Video
Published on 05/07/2026 at 15:15, 7 hours 39 minutes ago

ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 22:05, 49 minutes ago

Univar Solutions Announces Leadership Evolution
Published on 05/07/2026 at 20:42, 2 hours 11 minutes ago

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 4 hours 8 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/07/2026 at 18:35, 4 hours 19 minutes ago

Seminole Hard Rock Casino Named Official Miami World Cup 2026™ Host City Supporter
Published on 05/07/2026 at 18:00, 4 hours 54 minutes ago

Correction d’un communiqué du 05.05.2026 21:46 CET/CEST - E-PANGO: Composition du capital au 30 avril 2026

Les Echos

Published on 05/07/2026 at 19:15, 3 hours 39 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 hours 39 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 hours 48 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 hours 48 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 hours 54 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE